Skip to main content

Table 3 Markers of bone turnover: OC, CTX, BALP, P1NP at baseline, endpoint and the change following intervention1

From: Effect of vitamin D fortified foods on bone markers and muscle strength in women of Pakistani and Danish origin living in Denmark: a randomised controlled trial

 DanishPakistani 
 Placebo (n = 35)Fortified (n = 31)Placebo (n = 37)Fortified (n = 33)P2
OC (μg/L)
 Baseline23.9 (9.6)d25.2 (8.7)bc19.6 (8.4)c18.2 (5.6)bd0.001
 Endpoint22.3 (9.0)22.7 (6.8)b19.5 (8.9)17.4 (5.0)b0.03
 Change−1.2 (4.2)−2.3 (4.6)−0.20 (4.0)−0.5 (2.9)0.19
CTX (ng/mL)
 Baseline0.25 (0.14)0.30 (0.15)0.27 (0.19)0.21 (0.1)0.13
 Endpoint0.23 (0.14)0.26 (0.12)0.24 (0.16)0.19 (0.1)0.20
 Change−0.006 (0.1)− 0.05 (0.1)− 0.03 (0.1)− 0.02 (0.1)0.38
BALP (μg/L)
 Baseline15.5 (7.0)16.6 (5.2)15.9 (5.2)16.9 (7.9)0.79
 Endpoint13.4 (5.4)14.0 (4.4)14.6 (4.9)14.6 (6.0)0.74
 Change−1.5 (3.5)−1.5 (3.6)− 1.4 (2.1)− 1.8 (4.5)0.97
P1NP (μg/L)
 Baseline50.7 (25.2)54.6 (19.6)46.6 (19.6)48.1 (17.2)0.42
 Endpoint46.4 (23.8)51.1 (16.8)48.5 (21.0)45.7 (14.7)0.72
 Change−2.0 (7.9)−2.6 (11.0)1.7 (10.3)−1.7 (10.4)0.31
  1. 1Means and SD unless otherwise specified.
  2. 2P values for comparisons over the four study groups were determined with the use of a one-way ANOVA followed by Tukey’s HSD test. Significant comparisons a: DK Placebo vs DK Fortified, b: PA Fortified vs DK Fortified, c: PA Placebo vs DK Fortified, d: PA Fortified vs DK Placebo, e: PA Placebo vs DK Placebo, f: PA Placebo vs PA Fortified.
  3. OC Osteocalcin, BALP Bone specific Alkaline Phosphatase, P1NP Procollagen type 1 amino-terminal propeptide, CTX C-terminal crosslinked telopeptide of type 1 collagen